Search Results - "CAMACHO, Luis H"

Phase I/II Trial of Tremelimumab in Patients With Metastatic Melanoma by CAMACHO, Luis H, ANTONIA, Scott, RIBAS, Antoni, SOSMAN, Jeffrey, KIRKWOOD, John M, GAJEWSKI, Thomas F, REDMAN, Bruce, PAVLOV, Dmitri, BULANHAGUI, Cecile, BOZON, Viviana A, GOMEZ-NAVARRO, Jesus

“…Cytotoxic T lymphocyte-associated antigen 4 (CTLA4) blockade with tremelimumab (CP-675,206), a fully human anti-CTLA4 monoclonal antibody, was tolerated and…”
Get full text

Antitumor Activity in Melanoma and Anti-Self Responses in a Phase I Trial With the Anti-Cytotoxic T Lymphocyte–Associated Antigen 4 Monoclonal Antibody CP-675,206 by RIBAS, Antoni, CAMACHO, Luis H, SHARMA, Amarnath, GLASPY, John A, GOMEZ-NAVARRO, Jesus, LOPEZ-BERESTEIN, Gabriel, PAVLOV, Dmitri, BULANHAGUI, Cecile A, MILLHAM, Robert, COMIN-ANDUIX, Begona, REUBEN, James M, SEJA, Elisabeth, PARKER, Charla A

“…Cytotoxic T lymphocyte-associated antigen 4 (CTLA4) blockade with CP-675,206, a fully human anti-CTLA4 monoclonal antibody, may break peripheral immunologic…”
Get full text

Safety and Immunogenicity of Heat-Treated Zoster Vaccine (ZVHT) in Immunocompromised Adults by Mullane, Kathleen M., Winston, Drew J., Wertheim, Michael S., Betts, Robert F., Poretz, Donald M., Camacho, Luis H., Pergam, Steven A., Mullane, Michael R., Stek, Jon E., Sterling, Tina M., Zhao, Yanli, Manoff, Susan B., Annunziato, Paula W.

“…Background. Safety and immunogenicity of heat-treated zoster vaccine (ZV HT ) were assessed in immunocompromised adults. Methods. In a randomized,…”
Get full text

CTLA‐4 blockade with ipilimumab: biology, safety, efficacy, and future considerations by Camacho, Luis H.

“…Melanoma remains a critical public health problem worldwide. Patients with stage IV disease have very poor prognosis and their 1‐year survival rate is only…”
Get full text

Current Status of Biosimilars in Oncology by Camacho, Luis H.

“…Four medicinal cancer biological blockbusters will end their patent lifespan by 2020. It is estimated that the total market for cancer biologicals will reach…”
Get full text

Hepatic resection for metastatic melanoma: distinct patterns of recurrence and prognosis for ocular versus cutaneous disease by Pawlik, Timothy M, Zorzi, Daria, Abdalla, Eddie K, Clary, Bryan M, Gershenwald, Jeffrey E, Ross, Merrick I, Aloia, Thomas A, Curley, Steven A, Camacho, Luis H, Capussotti, Lorenzo, Elias, Dominique, Vauthey, Jean-Nicolas

“…Resection of melanoma metastatic to the liver remains controversial. We evaluated the efficacy of hepatic resection in patients with metastatic ocular and…”
Get full text

Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma by Comin-Anduix, Begoña, Lee, Yohan, Jalil, Jason, Algazi, Alain, de la Rocha, Pilar, Camacho, Luis H, Bozon, Viviana A, Bulanhagui, Cecile A, Seja, Elisabeth, Villanueva, Arturo, Straatsma, Bradley R, Gualberto, Antonio, Economou, James S, Glaspy, John A, Gomez-Navarro, Jesus, Ribas, Antoni

“…CTLA4-blocking antibodies induce tumor regression in a subset of patients with melanoma. Analysis of immune parameters in peripheral blood may help define how…”
Get full text

A Phase I Clinical Trial of Darinaparsin in Patients with Refractory Solid Tumors by TSIMBERIDOU, Apostolia Maria, CAMACHO, Luis H, SCHWARTZ, Brian, KURZROCK, Razelle, VERSTOVSEK, Srdan, NG, Chaan, HONG, David S, UEHARA, Cynthia K, GUTIERREZ, Catalina, DARING, Shawn, STEVENS, Jan, KOMARNITSKY, Philip B

“…Purpose: Darinaparsin, an organic arsenic, targets essential cell survival pathways. We determined the dose-limiting toxicity (DLT) and maximum tolerated dose…”
Get full text

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer by Brahmer, Julie R, Tykodi, Scott S, Chow, Laura Q.M, Hwu, Wen-Jen, Topalian, Suzanne L, Hwu, Patrick, Drake, Charles G, Camacho, Luis H, Kauh, John, Odunsi, Kunle, Pitot, Henry C, Hamid, Omid, Bhatia, Shailender, Martins, Renato, Eaton, Keith, Chen, Shuming, Salay, Theresa M, Alaparthy, Suresh, Grosso, Joseph F, Korman, Alan J, Parker, Susan M, Agrawal, Shruti, Goldberg, Stacie M, Pardoll, Drew M, Gupta, Ashok, Wigginton, Jon M

“…Antibodies to PD-1 protein and to one of its ligands, PD-L1, have shown antitumor activity. Unleashing T cells from inhibitory signals may be a strategy to…”
Get full text

Multicenter phase II study of matured dendritic cells pulsed with melanoma cell line lysates in patients with advanced melanoma by Ribas, Antoni, Camacho, Luis H, Lee, Sun Min, Hersh, Evan M, Brown, Charles K, Richards, Jon M, Rodriguez, Maria Jovie, Prieto, Victor G, Glaspy, John A, Oseguera, Denise K, Hernandez, Jackie, Villanueva, Arturo, Chmielowski, Bartosz, Mitsky, Peggie, Bercovici, Nadège, Wasserman, Ernesto, Landais, Didier, Ross, Merrick I

“…Several single center studies have provided evidence of immune activation and antitumor activity of therapeutic vaccination with dendritic cells (DC) in…”
Get full text

Phase I Dose Escalation Study of Sodium Stibogluconate (SSG), a Protein Tyrosine Phosphatase Inhibitor, Combined with Interferon Alpha for Patients with Solid Tumors by Naing, Aung, Reuben, James M, Camacho, Luis H, Gao, Hui, Lee, Bang-Ning, Cohen, Evan N, Verschraegen, Claire, Stephen, Saneese, Aaron, Joann, Hong, David, Wheler, Jennifer, Kurzrock, Razelle

“…Sodium stibogluconate (SSG), a small molecule inhibitor of protein tyrosine phosphatases, combined with IFN-alpha-2b (IFN-α) inhibited solid tumor cell line…”
Get full text

Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab by Eroglu, Zeynep, Kim, Dae Won, Wang, Xiaoyan, Camacho, Luis H, Chmielowski, Bartosz, Seja, Elizabeth, Villanueva, Arturo, Ruchalski, Kathleen, Glaspy, John A, Kim, Kevin B, Hwu, Wen-Jen, Ribas, Antoni

“…Highlights • Few treatments for metastatic melanoma provide long term tumor regressions. • Response rate of 15.6% observed in 143 patients treated with…”
Get full text

First-in-human phase I dose escalation study of MK-8033 in patients with advanced solid tumors by Keedy, Vicki L., Lenz, Heinz-Josef, Saltz, Leonard, Whisenant, Jennifer G., Berlin, Jordan D., Camacho, Luis H.

“…Summary Background C-Met, which is frequently activated in multiple cancers, has been implicated in tumor formation, progression, metastasis, angiogenesis, and…”
Get full text

Malignant Mesothelioma: Natural History, Pathologic Features and Future Therapies by Camacho, Luis H., MD, MPH, Mora-Bowen, Ana, MS, Munden, Reginald, MD, Smythe, W. Roy, MD, Ordoñez, Nelson G., MD

Get full text

Novel therapies targeting the immune system: CTLA4 blockade with tremelimumab (CP-675,206), a fully human monoclonal antibody by Camacho, Luis H

“…Cytotoxic T lymphocyte-associated antigen 4 (CTLA4) is an activation-induced transmembrane receptor. Binding of CTLA4 to its natural ligands downregulates…”
Get more information

A Randomized, Open-Label, Safety and Exploratory Efficacy Study of Kanglaite Injection (KLTi) plus Gemcitabine versus Gemcitabine in Patients with Advanced Pancreatic Cancer by Schwartzberg, Lee S, Arena, Francis P, Bienvenu, Bryan J, Kaplan, Edward H, Camacho, Luis H, Campos, Luis T, Waymack, J Paul, Tagliaferri, Mary A, Chen, Michael M, Li, Dapeng

“…This study was designed to assess the safety and preliminary efficacy of KLTi plus gemcitabine in patients with locally advanced or metastatic pancreatic…”
Get full text

Dual inhibition of the vascular endothelial growth factor pathway: A phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors by Hong, David S., Garrido‐Laguna, Ignacio, Ekmekcioglu, Suhendan, Falchook, Gerald S., Naing, Aung, Wheler, Jennifer J., Fu, Siqing, Moulder, Stacy L., Piha‐Paul, Sarina, Tsimberidou, Apostolia M., Wen, YueJin, Culotta, Kirk S., Anderes, Kenna, Davis, Darren W., Liu, Wen, George, Goldy C., Camacho, Luis H., Percy Ivy, Susan, Kurzrock, Razelle

“…BACKGROUND The current study was conducted to evaluate the safety and biological activity of dual inhibition of the vascular endothelial growth factor (VEGF)…”
Get full text

Biosimilars 101: considerations for U.S. oncologists in clinical practice by Camacho, Luis H., Frost, Craig P., Abella, Esteban, Morrow, Phuong K., Whittaker, Sadie

“…Biosimilars of biologics used for cancer treatment and supportive care are expected to enter the U.S. market soon. Biosimilars will be highly similar to their…”
Get full text

Prospective assessment of the reliability, validity, and sensitivity to change of the functional assessment of cancer Therapy‐Melanoma questionnaire by Cormier, Janice N., Ross, Merrick I., Gershenwald, Jeffrey E., Lee, Jeffrey E., Mansfield, Paul F., Camacho, Luis H., Kim, Kevin, Webster, Kimberly, Cella, David, Palmer, J. Lynn

“…BACKGROUND. The authors previously developed a melanoma‐specific module for the Functional Assessment of Cancer Therapy (FACT‐Melanoma), a tool for the…”
Get full text

A randomized phase II study of cilengitide (EMD 121974) in patients with metastatic melanoma by Kim, Kevin B, Prieto, Victor, Joseph, Richard W, Diwan, Abdul H, Gallick, Gary E, Papadopoulos, Nicholas E, Bedikian, Agop Y, Camacho, Luis H, Hwu, Patrick, Ng, Chaan S, Wei, Wei, Johnson, Marcella M, Wittemer, Sabine M, Vardeleon, Anna, Reckeweg, Aaron, Colevas, A Dimitrios

“…Cilengitide (EMD 121974) is a selective inhibitor of integrins αvβ3 and αvβ5. The αvβ3 promotes the proliferation of tumor-associated endothelial cells and…”
Get full text